Haseeb Ahmad leaves Merck & Co to head rival's UK pharma activities

15 February 2017

A pharma veteran has switched from one of the industry’s giants to another to lead its UK pharmaceuticals business.

Haseeb Ahmad has been named managing director for the UK and Ireland for the pharmaceuticals business of Swiss pharma group Novartis (NOVN: VX), and the company’s country president for the UK.

Mr Ahmad joins Novartis UK from Merck & Co (NYSE: MRK), the pharma giant known outside North America as Merck Sharp & Dohme (MSD), where he was managing director for Greece, Cyprus and Malta. He brings almost 20 years of experience in the industry at a multi-country and global level, including more than 13 years based in the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK